A research team from Stanford University and other institutions focused on the enzyme 15-hydroxyprostaglandin dehydrogenase (15-PGDH), which is responsible for breaking down prostaglandin E2—a molecule that plays a key role in regenerative processes. Previous studies had shown that blocking this enzyme could rejuvenate muscle tissue or improve nerve regeneration. The new research extends these observations to articular cartilage, one of the most difficult tissues in the body to repair.
In aging mice, daily administration of a 15-PGDH inhibitor for one month led to clear regeneration of knee joint cartilage, improvements in its structure, and a reduction in degenerative features. Similar effects were observed in a model of post-traumatic knee osteoarthritis: local injections into the joint not only slowed disease progression but also reduced pain symptoms, assessed through gait analysis and responses to pressure.
Crucially, the authors did not limit their work to animal studies. The paper also describes experiments on human cartilage taken from patients with advanced knee osteoarthritis. Tissue samples treated with the 15-PGDH inhibitor for several days showed increased proteoglycan content, improved mechanical properties, and changes in the expression of genes associated with regeneration. Molecular and imaging analyses indicated that the therapy stimulated cartilage cell activity and promoted rebuilding of the extracellular matrix.
The researchers emphasize, however, that these are still preclinical findings. While the results are promising, translating such a therapy to human use will require further safety testing, dose optimization, and clinical trials. In particular, the long-term effects of blocking 15-PGDH will need careful evaluation, as the enzyme is involved in many biological processes.
Despite these caveats, the study has generated strong interest because osteoarthritis affects hundreds of millions of people worldwide, and current treatments focus mainly on pain relief rather than repairing damaged tissue. If these findings are confirmed in clinical trials, they could pave the way for the first truly regenerative therapies for arthritis, rather than treatments that address symptoms alone.